Open Access

Possible predictive significance of serum RalA autoantibodies on relapse‑free survival in patients with colorectal cancer

  • Authors:
    • Mitsunori Ushigome
    • Hideaki Shimada
    • Yoshihiro Nabeya
    • Fumiaki Shiratori
    • Hiroaki Soda
    • Nobuhiro Takiguchi
    • Isamu Hoshino
    • Akiko Kuwajima
    • Tomoaki Kaneko
    • Kimihiko Funahashi
  • View Affiliations

  • Published online on: November 26, 2020     https://doi.org/10.3892/mco.2020.2180
  • Article Number: 18
  • Copyright: © Ushigome et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

RalA protein, a member of the Ras superfamily of small GTPases, is a tumor antigen that induces serum RalA antibodies (s‑RalA‑Abs). The present study explored the clinicopathological and prognostic significance of s‑RalA‑Abs in patients with colorectal cancer. Serum samples were obtained from 314 patients with colorectal cancer at stage 0/I (n=71), stage II (n=86), stage III (n=78), stage IV (n=64) and recurrence (n=15). Samples were analyzed for the presence of s‑RalA‑Abs using ELISA. The cutoff optical density value was fixed at 0.324 (mean of heathy controls + 3 standard deviations). The overall positive rate for serum anti‑RalA antibodies was 14%. The presence of s‑RalA‑Abs was not significantly associated with clinicopathological characteristic factors. Additionally, the s‑RalA‑Abs(+) group demonstrated significantly poor relapse‑free survival rates. The s‑RalA‑Abs (+)/carcinoembryonic antigen (CEA)(+) group exhibited the worst prognosis and s‑RalA‑Abs(+)/CEA(+) was an independent risk factor for poor relapse‑free survival. Although the positive rate was not high, s‑RalA‑Abs may be a useful predictor of poor relapse‑free survival in patients with colorectal cancer.
View Figures
View References

Related Articles

Journal Cover

January-2021
Volume 14 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ushigome M, Shimada H, Nabeya Y, Shiratori F, Soda H, Takiguchi N, Hoshino I, Kuwajima A, Kaneko T, Funahashi K, Funahashi K, et al: Possible predictive significance of serum RalA autoantibodies on relapse‑free survival in patients with colorectal cancer. Mol Clin Oncol 14: 18, 2021
APA
Ushigome, M., Shimada, H., Nabeya, Y., Shiratori, F., Soda, H., Takiguchi, N. ... Funahashi, K. (2021). Possible predictive significance of serum RalA autoantibodies on relapse‑free survival in patients with colorectal cancer. Molecular and Clinical Oncology, 14, 18. https://doi.org/10.3892/mco.2020.2180
MLA
Ushigome, M., Shimada, H., Nabeya, Y., Shiratori, F., Soda, H., Takiguchi, N., Hoshino, I., Kuwajima, A., Kaneko, T., Funahashi, K."Possible predictive significance of serum RalA autoantibodies on relapse‑free survival in patients with colorectal cancer". Molecular and Clinical Oncology 14.1 (2021): 18.
Chicago
Ushigome, M., Shimada, H., Nabeya, Y., Shiratori, F., Soda, H., Takiguchi, N., Hoshino, I., Kuwajima, A., Kaneko, T., Funahashi, K."Possible predictive significance of serum RalA autoantibodies on relapse‑free survival in patients with colorectal cancer". Molecular and Clinical Oncology 14, no. 1 (2021): 18. https://doi.org/10.3892/mco.2020.2180